Acrisorcin

Summary

Acrisorcin (CHEMBL1201038) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 388.5 Da · C25H28N2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201038
Name	Acrisorcin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	24144
Molecular formula	C25H28N2O2
Molecular weight	388.5
InChIKey	YZODJQFXMFEJRM-UHFFFAOYSA-N

SMILES: CCCCCCC1=C(C=C(C=C1)O)O.C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)N

IUPAC name: acridin-9-amine;4-hexylbenzene-1,3-diol

Also known as: Acrisorcin, Acrisorcina, Acrisorcine, Akrinol, NSC-758691, SCH 7056, SCH-7056, SID26748936, ACRISORCIN

Patent coverage: 521 distinct patent families (1,956 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,954 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 13 (assay-derived). Sample: Microtubule-associated protein tau, Lysine-specific demethylase 4E, Ubiquitin carboxyl-terminal hydrolase 2, Nuclear receptor ROR-gamma, Ferritin light chain, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], Alpha-galactosidase A, Lysosomal alpha-glucosidase, Cytochrome P450 3A4, Caspase-7.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 14 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
USP2	6.3	Potency	501.2	nM	CHEMBL_ACT_4711612
CYP3A4	5.3	Potency	5012	nM	CHEMBL_ACT_4961382
CYP3A4	5.3	Potency	5012	nM	CHEMBL_ACT_5026871
P51450	5.2	Potency	6310	nM	CHEMBL_ACT_4100801

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).